Inhaled medication therapy for bronchiectasis: status quo and the next frontier

Click to increase image sizeClick to decrease image size

Declaration of interest

WJ Guan declares that he has received National Natural Science Foundation No. 81,400,010, Pearl River S&T Nova Program of Guangzhou No. 201,710,010,097, and Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme 2017. YH Gao declares that he has received National Natural Science Foundation No. 81,500,006. N Zhong and RC Chen declare that they have received Changjiang Scholars and Innovative Research Team in University ITR0961, The National Key Technology R&D Program of the 12th National Five-year Development Plan 2012BAI05B01 and National Key Scientific & Technology Support Program: Collaborative innovation of Clinical Research for chronic obstructive pulmonary disease and lung cancer No. 2013BAI09B09. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

One peer reviewer on this manuscript has declared that they are co-PI on two clinical trials for inhaled therapies for bronchiectasis (CLEAN-PCD study through Parion/Vertex and the Willow Study through INSMED), as well as a possible PI for the PROMIS II through Chiltern/Zambon.

Additional information

Funding

This paper was not funded.